Quest Diagnostics logo

Quest Diagnostics(NYSE) DGX

Market Cap$26.37BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1996)+9,607%
5 Year+83%
1 Year+37%
1 Month+4%
Premium Feature
Moneyball Superscore
77/100
$244.90
+2.50%
+5.97Today
After hours$238.42-$6.48 (-2.65%)
Quest Diagnostics last closing stock price
MetricPriceDate
Last closeUSD 243.282026-10-22
Quest Diagnostics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+1.73%USD 239.152026-10-15
1 month+4.01%USD 233.892026-09-22
3 month+7.16%USD 227.022026-07-24
Year to date+42.55%USD 170.662025-12-31
1 year+36.54%USD 178.172025-10-22
3 year+112%USD 114.762023-10-23
5 year+82.91%USD 133.002021-10-22
Since inception+9,606.5%USD 2.461996-12-17

Quest Diagnostics Financials at a Glance

Market Cap

$26.37BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$11.56B

Net Income (TTM)

$1.06B

EPS (TTM)

$9.43

P/E Ratio

25.34

Dividend

$3.38

Beta (Volatility)

0.34 (Low)

Price

$244.90

Volume

1,686,025.027

Open

$226.50

Previous Close

$243.28

Daily Range

$226.22 - $246.00

52-Week Range

$171.18 - $248.84

Estimated Earnings Date

Feb 4, 2027

DGX: Motley Fool Moneyball Superscore

77

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Quest Diagnostics

Quest Diagnostics Incorporated NYSE:DGX tests blood samples for doctors. These tests help people find and treat diseases early. The company also makes software for hospital health data.

What Does Quest Do?

  • Diagnostic Information Services: Lab testing for doctors, hospitals, and patients including routine and advanced pathology, which is the study of tissues and fluids; accounts for more than 95% of net revenues.
  • Risk Assessment Services: Solutions for life insurance companies to help them evaluate health risks for new insurance applicants.
  • Healthcare Information Technology: Software systems for clinicians and health plans to manage patient data, billing, and order processing.

Growing the Network

  • Formed a new entity with Corewell Health in Jan. 2026 to provide lab testing services in Michigan.
  • Increased testing volume through an expanded relationship with dialysis clinics owned by Fresenius Medical Care.
  • Completed a $500 million senior notes offering in May 2026 to pay down existing debt.
  • Authorized an additional $1 billion for the repurchase of common stock in Feb. 2026.

Modernizing for the Future

The company uses its Invigorate program to automate laboratory operations and improve productivity, aiming for 3% annual cost savings. It also runs Project Nova to modernize technology systems and improve patient experiences during the testing process.

Key Financial Results

  • Net revenues reached $3.04 billion for the three months ended June 30, 2026, up 10.2% year over year.
  • Net income was $320 million for the three months ended June 30, 2026, up 13.4% year over year.
  • Net cash from operations reached $875 million for the six months ended June 30, 2026, up $17 million year over year.
  • Diluted earnings per share were $2.84 for the three months ended June 30, 2026, up 15.0% year over year.

Bottom Line

Quest has evolved from a laboratory provider into a health information company. Its use of automated technology and large-scale data supports its central role in the domestic healthcare system.

AI Generated • Jul 24, 2026

Industry

Healthcare Providers and Services

Employees

57,000

CEO

James E. Davis

Headquarters

Secaucus, NJ 07094, US

DGX Financials

Key Financial Metrics (TTM)

Gross Margin

33.15%

Operating Margin

14.14%

Net Income Margin

9.19%

Return on Equity

14.49%

Return on Capital

11.38%

Return on Assets

6.27%

Earnings Yield

3.95%

Dividend Yield

1.41%

Payout Ratio

34.18%

Stock Overview

Market Cap

$26.37BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

110.37M

Volume

1.69M

Avg. Volume

1.06M

Financials (TTM)

Gross Profit

$3.83B

Operating Income

$1.64B

EBITDA

$2.23B

Operating Cash Flow

$1.77B

Capital Expenditure

-$554.00M

Free Cash Flow

$1.22B

Cash & ST Invst.

$626.00M

Total Debt

$6.38B

Quest Diagnostics Performance Analysis

Quest Diagnostics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 9,883,000,000-8.4%
20232023-12-31USD 9,252,000,000-6.4%
20242024-12-31USD 9,872,000,0006.7%
20252025-12-31USD 11,035,000,00011.8%
Quest Diagnostics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-302.0%
Q42025-12-31-0.4%
Q12026-03-313.2%
Q22026-06-305.1%
Quest Diagnostics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 7.98-48.6%
20232023-12-31USD 7.52-5.8%
20242024-12-31USD 7.661.9%
20252025-12-31USD 8.7414.1%
Quest Diagnostics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-12.6%
Q42025-12-310.9%
Q12026-03-312.8%
Q22026-06-3026.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$3.04B

+10.2%

Gross Profit

$1.03B

+8.9%

Gross Margin

33.75%

N/A

Market Cap

$26.37BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$512.07K

N/A

Employees

51,500

N/A

Net Income

$320.00M

+13.5%

EBITDA

$589.00M

-1.2%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$626.00M

+96.2%

Total Debt

$6.38B

-0.0%

Accounts Receivable

$1.67B

+17.4%

Inventory

$233.00M

+24.6%

Long Term Debt

$6.19B

+8.5%

Short Term Debt

$190.00M

-71.9%

Return on Assets

6.27%

N/A

Return on Invested Capital

10.79%

N/A

Free Cash Flow

$330.00M

-24.3%

Operating Cash Flow

$468.00M

-14.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
LHLabcorp Holdings Inc.
$329.93+1.91%
GHGuardant Health, Inc.
$162.94-2.23%
RVTYRevvity, Inc.
$157.36+0.48%
ILMNIllumina, Inc.
$269.40-4.76%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$7.88-14.81%
SPCXSpace Exploration Technologies
$144.75-9.14%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$82.11-20.47%
INTCIntel
$85.49-8.04%

Questions About DGX

What is the current price of Quest Diagnostics?

Quest Diagnostics is trading at $243.28 per share.

What is the 52-week range for Quest Diagnostics?

Over the past 52 weeks, Quest Diagnostics has traded between $171.18 and $248.84.

How much debt does Quest Diagnostics have?

As of the most recent reporting period, Quest Diagnostics reported total debt of $6.29B.

How much cash does Quest Diagnostics have on hand?

Quest Diagnostics reported $797.00M in cash and cash equivalents in its most recent financial results.

What is Quest Diagnostics’s dividend yield?

Quest Diagnostics currently has a dividend yield of 1.41%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.